WallichosideCAS# 60657-36-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
| Cas No. | 60657-36-5 | SDF | Download SDF |
| PubChem ID | N/A | Appearance | Powder |
| Formula | C20H28O8 | M.Wt | 396.43 |
| Type of Compound | Sesquiterpenoids | Storage | Desiccate at -20°C |
| Synonyms | (2S,3S)-Pterosin C 3-O-β-glucopyranoside,NSC 280410 | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Wallichoside Dilution Calculator
Wallichoside Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5225 mL | 12.6126 mL | 25.2251 mL | 50.4503 mL | 63.0628 mL |
| 5 mM | 0.5045 mL | 2.5225 mL | 5.045 mL | 10.0901 mL | 12.6126 mL |
| 10 mM | 0.2523 mL | 1.2613 mL | 2.5225 mL | 5.045 mL | 6.3063 mL |
| 50 mM | 0.0505 mL | 0.2523 mL | 0.5045 mL | 1.009 mL | 1.2613 mL |
| 100 mM | 0.0252 mL | 0.1261 mL | 0.2523 mL | 0.5045 mL | 0.6306 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2,3-Dihydro-3-hydroxy-2-oxo-1H-indole-3-acetic acid
Catalog No.:BCX1714
CAS No.:57061-17-3
- Protoapigenin
Catalog No.:BCX1713
CAS No.:879325-07-2
- 2-(trans-1,4-dihydroxy-cyclohexyl)-5,7-dihydroxy-chromone
Catalog No.:BCX1712
CAS No.:1270013-29-0
- Protoapigenin 4'-O-β-D-glucoside
Catalog No.:BCX1711
CAS No.:163559-04-4
- Angulatin E
Catalog No.:BCX1710
CAS No.:403613-20-7
- Angulatin G
Catalog No.:BCX1709
CAS No.:1000784-46-2
- Celangulatin C
Catalog No.:BCX1708
CAS No.:1000784-44-0
- Apigenin 4'-O-β-D-glucopyranoside
Catalog No.:BCX1707
CAS No.:20486-34-4
- Epinodosinol
Catalog No.:BCX1706
CAS No.:27548-88-5
- (1α,2α,6β,8α,9α)-1,2,6,8,12-pentakis(acetyloxy)-9-(benzoyloxy)dihydro-β-agarofuran
Catalog No.:BCX1705
CAS No.:128443-60-7
- Caffeic acid tetramer
Catalog No.:BCX1704
CAS No.:130286-75-8
- Celangulin V
Catalog No.:BCX1703
CAS No.:139979-81-0
- Rabdophyllin G
Catalog No.:BCX1716
CAS No.:82460-75-1
- Angulatin K
Catalog No.:BCX1717
CAS No.:1631992-80-7
- (2E,4E)-8-Hydroxy-2,7-dimethyl-decadien-(2,4)-disaeure-(1,10)-dioic acid
Catalog No.:BCX1718
CAS No.:2808401-10-5
- Aristol-1(10)-en-9-ol
Catalog No.:BCX1719
CAS No.:114339-94-5
- Maritimetin
Catalog No.:BCX1720
CAS No.:576-02-3
- Polyporoid B
Catalog No.:BCX1721
CAS No.:1042362-45-7
- Polyporoid C
Catalog No.:BCX1722
CAS No.:1042362-47-9
- 2R-3',4',8-Trihydroxyflavanone-7-O-glucoside
Catalog No.:BCX1723
CAS No.:56389-87-8
- 2',3'-Dihydro-2'-hydroxyprotoapigenone
Catalog No.:BCX1724
CAS No.:1365655-88-4
- Angulatin B
Catalog No.:BCX1725
CAS No.:142546-07-4
- Celangulin XIX
Catalog No.:BCX1726
CAS No.:403505-80-6
- Arabidopyl alcohol
Catalog No.:BCX1727
CAS No.:1400234-92-5
Identification of BMI1 Promoter Inhibitors from Beaumontia murtonii and Eugenia operculata.[Pubmed:28598616]
J Nat Prod. 2017 Jun 23;80(6):1853-1859.
B-Cell-specific Moloney murine leukemia virus insertion region 1 (BMI1) is a core component of the polycomb repressive complex 1 (PRC1). Abnormal expression of BMI1 is associated with a number of human malignances and cancer stem cells (CSCs), which cause chemotherapy resistance. Therefore, small molecules that inhibit BMI1 expression are potential candidates for cancer therapy. In this study, a cell-based reporter gene assay was developed that allowed BMI1 promoter activity to be measured in 293T human embryonic kidney cells based on luciferase expression levels. Using this screening assay, the methanol-soluble extracts of Beaumontia murtonii and Eugenia operculata were selected as leads. Bioassay-guided fractionation of the extracts led to the isolation of three known cardenolides (1-3) and one new compound (4) from B. murtonii and two known triterpenoids (5 and 6) and one new compound (7) from E. operculata. These seven compounds inhibited BMI1 promoter activity (IC(50) range 0.093-23.0 muM), and the most active compound, Wallichoside (1), was further evaluated. Western blot analysis revealed that Wallichoside (1) decreases BMI1 protein levels in HCT116 human colon carcinoma cells, and flow cytometry analysis showed that it significantly reduced levels of the CSC biomarker epithelial cell adhesion molecule. Wallichoside (1) also inhibited sphere formation of Huh7 human hepatocellular carcinoma cells, indicating that it diminished the self-renewal capability of CSCs.
Chemical and biologically active constituents of Pteris multifida.[Pubmed:18553125]
J Nat Med. 2008 Oct;62(4):452-5.
A new compound, 4-caffeoyl quinic acid 5-O-methyl ether (2), together with 12 known compounds--identified as (2R,3R)-pterosin L 3-O-beta-D-glucopyrannoside (3), beta-sitosterol beta-D-glucopyranoside (4), apigenin 7-O-beta-D-glucopyranoside (5), luteolin 7-O-beta-D-glucopyranoside (6), sucrose (7), caffeic acid (8), pterosin C 3-O-beta-D-glucopyranoside (9), pteroside C (10), 4,5-dicaffeoyl quinic acid (11), pteroside A (12), Wallichoside (13) and (2S)-5,7,3',5'-tetrahydroxyflavanone (14)--were isolated from Pteris multifida. The structure of the new compound was determined by means of physical, chemical and spectroscopic evidence. Compounds 5 and 6 were the main constituents of the plant, with yields of 0.19% and 0.16%, respectively. The cytotoxic activities of 2, 3, and 9-13 were evaluated against a human cell line (KB cells). Among the isolated compounds, pterosin C 3-O-beta-D-glucopyrannoside (9) and 4,5-dicaffeoylquinic acid (11) showed a significant selective cytotoxicity (IC(50) 2.35 and 5.38, respectively), while moderate activity was observed for compound 2 (IC(50) 12.3). The chemosystematics of Pteris species is also discussed.
